Trials / Completed
CompletedNCT01076179
Kaletra in Combination With Antiretroviral Agents
KALETRA in Combination With New Substances (PROTEKT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 502 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the tolerability of Kaletra (lopinavir/ritonavir) in combination with new substances such as integrase inhibitors (INIs), C-C chemokine receptor type 5 (CCR5) antagonists, and new non-nucleoside reverse transcriptase inhibitors (NNRTIs), as there are many reasons (intolerability, complex resistant patterns or even personal reasons) which may result in a change from the daily clinical routine and lead to the use of a newly approved antiretroviral agent in combination with Kaletra.
Detailed description
This study was designed as a non-interventional observational study. Kaletra was prescribed in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines.
Conditions
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2010-02-26
- Last updated
- 2017-05-19
- Results posted
- 2017-05-19
Source: ClinicalTrials.gov record NCT01076179. Inclusion in this directory is not an endorsement.